ADMINISTRATION OF PERIPHERAL BLOOD T-CELLS AND EBV SPECIFIC CTLS TRANSDUCED TO
ADMINISTRATION OF PERIPHERAL BLOOD T-CELLS AND EBV SPECIFIC CTLS TRANSDUCED TO
批准号:
7605876
负责人:
HEIDI V RUSSELL
金额:
$0.47万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-02-15 至 2007-11-30
关键词:
AffectAge-YearsAutologousCellsChildChildhood Solid NeoplasmComputer Retrieval of Information on Scientific Projects DatabaseDiseaseDisease remissionDoseEBV-Specific Cytotoxic T-LymphocyteFailureFundingGrantInfantInstitutionLeadLocalizedLocalized DiseaseLong-Term SurvivorsMethodsMonoclonal AntibodiesNeuroblastomaOutcomePTPRC genePatientsPhaseRadiation therapyRateRelapseResearchResearch PersonnelResourcesSafetySourceSpontaneous RemissionStem cellsSubgroupT-LymphocyteUnited StatesUnited States National Institutes of Healthcell typeimmunoregulationimprovedin vivointerestoutcome forecastperipheral bloodreceptortumor
中文摘要
这个子项目是许多研究子项目中利用
资源由NIH/NCRR资助的中心拨款提供。子项目和
调查员(PI)可能从NIH的另一个来源获得了主要资金,
并因此可以在其他清晰的条目中表示。列出的机构是
该中心不一定是调查人员的机构。
神经母细胞瘤是儿童最常见的颅外实体肿瘤,在美国每年约有600名儿童受到影响。当肿瘤发生在婴儿(1岁以下儿童)时,它通常是局部性的,对治疗有很好的反应。即使是播散性疾病也可以在大约75%的婴儿中根除,实际上,可能会自发缓解。在年龄较大的儿童(1岁以上)中,预后要差得多。虽然局部疾病患者仍可通过常规治疗治愈,但70%或更多的播散性肿瘤患者有望在3年内复发,这一亚群几乎不会成为长期幸存者。在过去的十年里,改善晚期神经母细胞瘤预后的努力集中在更大程度上加强化疗的诱导和巩固阶段,无论有没有干细胞拯救。尽管缓解率有所提高,但长期存活率仍然很低。这一失败导致了人们对替代根除疾病方法的兴趣重新燃起,免疫调节作为一种特殊的选择。
本研究的主要目的是:1)评价CD45单抗去除淋巴组织后,递增剂量14g2a.zeta嵌合受体转导的自体EB病毒特异性细胞毒性T淋巴细胞(EBV-CTL)和14g2a.zeta转导的自体外周血T细胞的安全性。第二个目标是:1)确定这两种类型的细胞在体内的存活和功能的差异,特别是确定嵌合受体转导的EBV-CTL是否比转导的外周血T细胞存活时间更长;以及2)确定转导的外周血T细胞和EBV特异性CTL在体内的抗肿瘤作用。
英文摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
Neuroblastoma, the most common extracranial solid tumor of childhood, affects approximately 600 children a year in the United States. When the tumor occurs in infants (children under 1 year of age), it is frequently localized and responds well to therapy. Even disseminated disease can be eradicated in about 75% of infants and, indeed, may undergo spontaneous remission. In older children (over 1 year of age), the prognosis is far worse. Although patients with localized disease may still be cured by conventional therapy, 70% or more of those with disseminated tumor can be expected to relapse within 3 years, and virtually none of this subgroup will become long-term survivors. Over the past decade, attempts to improve the outcome of advanced neuroblastoma have focused on greater intensification of the induction and consolidation phases of chemo-radiotherapy, with or without stem cell rescue. Despite improvements in remission rates, long term survival remains poor. This failure has lead to a resurgence of interest in alternative methods of disease eradication, immune modulation as one particular option.
The primary objectives of this study are: 1) To evaluate the safety of escalating doses of 14g2a.zeta chimeric receptor transduced autologous EBV specific cytotoxic T-lymphocytes (EBV-CTL) and 14g2a.zeta transduced autologous peripheral blood T-cells in patients with neuroblastoma who have been lymphodepleted by CD45 monoclonal antibodies (MAbs). Secondary objectives are: 1) To determine the differential survival and function of these two infused cell-types in vivo, in particular to determine if chimeric receptor transduced EBV-CTLs survive longer than transduced peripheral-blood T-cells; and 2) To determine anti-tumor effects of transduced peripheral blood T-cells and EBV specific CTLs in vivo.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CLINICAL TRIAL: NANT 2004-04: PHASE I STUDY OF FENRETINIDE (4-HPR, NSC 374551)
-
批准号:7950616
-
项目类别:
-
资助金额:$0.06万
-
财政年份:2008
-
负责人:HEIDI V RUSSELL
-
依托单位:
CLINICAL TRIAL: A PHASE I STUDY OF ZOLEDRONIC ACID (ZOMETA) WITH CYCLOPHOSPHAMID
-
批准号:7950608
-
项目类别:
-
资助金额:$0.12万
-
财政年份:2008
-
负责人:HEIDI V RUSSELL
-
依托单位:
A PHASE I STUDY OF ZOLEDRONIC ACID (ZOMETA) WITH CYCLOPHOSPHAMIDE IN CHILDREN
-
批准号:7605896
-
项目类别:
-
资助金额:$0.91万
-
财政年份:2007
-
负责人:HEIDI V RUSSELL
-
依托单位:
ADMINISTRATION OF PERIPHERAL BLOOD T-CELLS AND EBV SPECIFIC CTLS
-
批准号:7374994
-
项目类别:
-
资助金额:$0.62万
-
财政年份:2005
-
负责人:HEIDI V RUSSELL
-
依托单位:
Pilot Study of 1A7 Antibody as Vaccine for Patients with Advanced Neuroblastoma
-
批准号:7041654
-
项目类别:
-
资助金额:$0.09万
-
财政年份:2003
-
负责人:HEIDI V RUSSELL
-
依托单位:
Gene Modified Autologous Neuroblastoma Vaccine for Remission Neuroblastoma
-
批准号:7041649
-
项目类别:
-
资助金额:$2.51万
-
财政年份:2003
-
负责人:HEIDI V RUSSELL
-
依托单位:
海外基金